SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Spero Therapeutics, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration revenue | $0 | $0 | $12.57M | $0 | $0 | $12.00K | $52.00K | $65.00K | $114.00K | $140.00K | – | – |
| Collaboration revenue - related party | $0 | $258.00K | $27.08M | $3.05M | $11.80M | $5.10M | $9.30M | $7.75M | $5.90M | $4.06M | – | -100.0% |
| Grant Revenue | $0 | $0 | $1.64M | $2.39M | $2.39M | $763.00K | $5.69M | $5.65M | $4.18M | $5.06M | – | -100.0% |
By region
From the segment and revenue-disaggregation notes of Spero Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.